Investment Thesis
Cytokinetics exhibits severe financial distress with negative stockholders equity (-$826.6M), catastrophic cash burn (-$151.4M FCF annually), and operating losses exceeding -$180M, significantly outpacing the recent 376% revenue growth ($19.4M). At current burn rates, cash reserves ($129.8M) provide less than 10 months of runway, necessitating capital raises or immediate path to profitability.
Strengths
- Exceptional revenue growth of 376.6% YoY indicates market traction and potential commercialization
- Strong short-term liquidity position with 4.21x current ratio
- Adequate cash reserves of $129.8M for near-term operational needs
Risks
- Negative stockholders equity of -$826.6M indicates balance sheet insolvency and unsustainable capital structure
- Operating cash burn of -$145.5M annually with only $129.8M cash reserves creates existential survival risk within 1 year
- Long-term debt of $247.2M with negative interest coverage (-4.0x) cannot be serviced from operations
- Operating margin of -948.7% and net margin of -1064.5% indicate business model not yet viable at scale
- Clinical/regulatory execution risk inherent in pharmaceutical development stage company
Key Metrics to Watch
- Runway to cash depletion and timing/success of capital raises
- Path to operating cash flow breakeven and timeline to profitability
- Revenue growth sustainability and gross margin expansion as volumes increase
- Clinical trial outcomes and regulatory approval trajectory for pipeline
Financial Metrics
Revenue
19.4M
Net Income
-206.0M
EPS (Diluted)
$-1.67
Free Cash Flow
-151.4M
Total Assets
1.3B
Cash
129.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-948.7%
Net Margin
-1,064.5%
ROE
N/A
ROA
-16.2%
FCF Margin
-782.2%
Balance Sheet & Liquidity
Current Ratio
4.21x
Quick Ratio
4.21x
Debt/Equity
N/A
Debt/Assets
164.9%
Interest Coverage
-4.03x
Long-term Debt
247.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T08:36:06.889223 |
Data as of: 2026-03-31 |
Powered by Claude AI